Introduction {#S1}
============

Cryptorchidism (CO) or undescended testis (OMIM\#219050), is the most common genitourinary malformation in newborn males. Many reports indicate that boys with CO have an overall relative risk (RR) of 4.8 (95% confidence interval 4.0--5.7) of develop testicular germ cell tumors (TGCT, OMIM\#273300; [@B8]; [@B16]), which is the most frequent solid tumor in men between 15 and 44 years of age. TGCT is classified generally as seminoma (sTGCT) and non-seminoma (nsTGCT; [@B16]). Although the association of CO and TGCT has been clinically established, the mechanisms leading to carcinogenesis are still unknown ([@B9]). Due to the presence of common genetic factors in the etiology of both pathologies, it is possible infer the existence of a molecular genetic relationship between CO and the development of TGCT ([@B31]).

Studies that have been focused on searching diagnostic markers for TGCT proposed several single nucleotide variants (SNVs) in genes such as *POU5F1*, *DND1*, *KIT*, *KITLG*, *AR*, *DMTR1*, *SPRY4*, *BCL2*, *NANOG*, *TGFBR2*, *PTEN*, *AKT1*, *PDE11A*, *GATA4*, and *THOC1* ([@B5]; [@B30]; [@B17]; [@B19]). Proto-oncogene tyrosine kinase receptor (*KIT*) and the androgen receptor (*AR*) are relevant in the development of TGCT. Although it has not been shown that genetic variants in these genes are responsible for causing CO or Germ cell neoplasia *in situ* (*GCNIS*) a precursor lesion to TGCT, both genes have a role in testicle development and testicular carcinogenic process, influencing directly as in the case of *AR*, through non-genomic pathways ([@B32]). The *KIT* gene codifies a class III homodimeric receptor with tyrosine kinase activity in humans. KIT is activates by its ligand KITLG codified by the *KITLG* gene ([@B1]). Both, receptor and ligand are essential for survival, migration and differentiation of the early germ cells (gonocytes; [@B28]). Currently, gonocytes have been proposed as responsible for the development of *GCNIS* ([@B31]; [@B4]). On the other hand, the *AR* gene produces a homodimeric cytosolic nuclear receptor, which binds to androgens and induces gene transcription ([@B18]; [@B7]). AR is essential in the inguinal-scrotal phase of testicular descent during the male fetal stage by controlling the normal gonocyte proliferation in the testis ([@B22]; [@B15]). Interestingly, AR is overexpressed in *GCNIS* and it has been found in gonocytes unable to differentiate properly ([@B22]).

Although several studies clearly show a high risk of develop testicular neoplasia in patients with CO, there are no studies that correlate SNVs in patients with TGCT and CO. Therefore, the aims of this study were to analyze the relevant common clinical features in Mexican patients with isolated CO and TGCT, and to identify SNVs in the *KIT* and *AR* genes by allelic discrimination in patients with TGCT and history of CO. This study reports clinical features and genetic variant that may support the early diagnosis of TGCT in pediatric patients with isolated CO.

Materials and Methods {#S2}
=====================

Subjects {#S2.SS1}
--------

The study included 328 individuals referred to the Urology Service of the National Institute of Pediatrics and National Institute of Cancerology in Mexico, from 2006 to 2017. The patients were divided in two groups as follows: the first group consisted in 91 patients with confirmed diagnosis of isolated or non-syndromic CO; the second group included 79 patients with confirmed diagnosis of TGCT, 66 of them without history of CO, and 13 patients with confirmed history of isolated CO. In all patients the diagnosis were validated by clinical history, physical examination and imaging studies in all cases. Subsequently, clinical data was obtained and patients were classified according to clinical features. In addition, 158 healthy men without history of CO or TGCT were included as a control group.

All patients and healthy men were Mexican descent, at least two generations, with 46, XY normal karyotype. This study is part of the project with registration number INP-01/2016, approved by the Research and Ethic Committee of INP and all patients included in the study had previously signed the informed consent.

Genotyping of Allelic Variants {#S2.SS2}
------------------------------

DNA was obtained from peripheral blood sample from patients with CO, patients with TGCT without history of CO and healthy individuals according to standard protocols QIA-AMP DNA blood mini kit, \[Qiagen, Vienna, Austria\]. DNA from patients with both conditions (TGCT and history of CO) was obtained from the testicular tumor samples embedded in paraffin a according to the manufacturer's protocol FFPE RNA/DNA Purification Plus Kit, \[Norgen Biotec Corp, Ontario, Canada\]. Subsequently, DNA samples were used for genotyping analysis of rs121913507 (D816V), rs121913506 (D816H), and rs121913514 (N822K) SNVs in the *KIT* gene and rs201934623 (P392S), rs774171864 (A299T), and rs12014709 (g.67718624T \> G) SNVs in the *AR* gene. The genotyping was performed through allelic discrimination according to established protocol of TaqMan \[BMG chemistry Applied Biosystems, Foster City, CA, United States\]. The genotyping rate was 99.9% and 30% of the randomized samples, which showed 100% reproducibility in duplicate trials for the 6 SNVs.

Statistical Analysis {#S2.SS3}
--------------------

The comparison between the genotypes obtained and the clinical data was performed using SPSS v21 statistical package. Chi-square test or Fisher's exact test were used for the SNVs analysis in different groups; in all cases, the *P* value \< 0.05 was considered significant. The statistical power was calculated from the frequency of the minor allele of the variants with a significant *P* value due to the small number of individuals included in this study. Finally, the allelic frequencies of the SNVs in the population were compared with the frequencies reported in other populations in the HapMap and in the project of the 1000 genomes of European Ancestry (EUR), African Ancestry (AFR), East Asian Ancestry (EAS), South Asian Ancestry (SAS), Latino Ancestry (AMR), and Mexican Ancestry in Los Angeles (MXL).

Analysis of Linkage Disequilibrium and Haplotypes {#S2.SS4}
-------------------------------------------------

Haplotype association analysis was performed with the variants located in the same gene. Those variants with a *D*' value equal or greater than 0.8 were considered in linkage disequilibrium (LD) and haplotypes formed by our cases and controls were compared using Haploview 4.2 software ([@B3]), and then correlating only the patients with bilateral and unilateral CO phenotypes. The epistasis between variants located in different loci were assayed by a Multifactor Dimensionality Reduction (MDR) method in the MDR 3.0.2 software ([@B23]), since all *P* values were greater than 0.05 and Cross Validation (CV) values equal to 10/10, were considered.

Analysis of Population Structure {#S2.SS5}
--------------------------------

The analysis of rs121913506 (D816H), rs121913514, rs774171864, and rs12014709 SNVs in 328 individuals were performed. The software STRUCTURE 2.3.4. (Pritchard Lab, Stanford University) was used to test the stratification within the samples. A mixing model consisting of a burning period of 1,000,000 and 1,000,000 repetitions with a *k* = 2 was used. It should be noted that, although the ancestry informative markers (AIMS) analysis was not performed, the SNVs allowed us to evidence the structural phenomenon of our population. The value of δ \> 1 indicated that majority of the analyzed individuals were mixed ([@B25]).

Results {#S3}
=======

Clinical Features Associated to CO and TGCT {#S3.SS1}
-------------------------------------------

At the time of diagnosis, the patients with CO (*n* = 91) had an average age of 3.5 ± 0.3 years, and those with TGCT had 26.5 ± 0.9 years \[TGCT with CO (*n* = 13) = 24.3 ± 2.5 years, and TGCT without CO (*n* = 66) = 26.9 ± 1.0 years\].

In patients with CO, the frequency of bilateral CO was 48.3% (44/91); all patients with CO underwent orchidopexy, but 73.6% (68/91) underwent orchidopexy after 18 months of age (2--16 years; data not shown), and only 16.5% (15/91) required orchiectomy due to the presence of testicular atrophy ([Table 1](#T1){ref-type="table"}). In addition, 13.2% (12/91) of the patients reported family history of CO and only 2.2% (2/91) reported family history of TGCT ([Table 1](#T1){ref-type="table"}).

###### 

Clinical features of the patients.

  Clinical features             Patients with isolated CO *n* = 91 (%)   Patients with TGCT *n* = 79                
  ----------------------------- ---------------------------------------- ----------------------------- ------------ -----------
  Age at diagnosis              3.5 ± 0.3                                24.3 ± 2.5                    26.9 ± 1.0   
  CO                            Bilateral                                44 (48.3)                     7 (53.8)     NA
                                Left                                     25 (27.5)                     3 (23.1)     
                                Right                                    22 (24.2)                     3 (23.1)     
  Orchidopexy                   Yes                                      91 (100)                      5 (38.5)     NA
                                No                                       0 (0)                         8 (61.5)     
  Orchiectomy                   Yes                                      15 (16.5)                     13 (100)     66 (100)
                                No                                       76 (83.5)                     0 (0)        0 (0)
  Family history of CO          Positive                                 12 (13.2)                     0 (0)        0 (0)
                                Negative                                 79 (86.8)                     13 (100)     66 (100)
  Family history of TGCT        Positive                                 2 (2.2)                       0 (0)        3 (4.5)
                                Negative                                 89 (97.8)                     13 (100)     63 (95.5)
  TGCT                          Bilateral                                NA                            1 (7.7)      0 (0)
                                Left                                                                   4 (30.8)     36 (54.5)
                                Right                                                                  8 (61.5)     30 (45.5)
  Clinical stage at diagnosis   I                                        NA                            4 (30.8)     33 (50)
                                II                                                                     7 (53.8)     15 (21.7)
                                III                                                                    1 (7.7)      12 (18.2)
                                IV                                                                     1 (7.7)      6 (9.1)
  Metastasis                    Positive                                 NA                            7 (53.8)     24 (36.4)
                                Negative                                                               6 (46.2)     42 (63.6)
  Tumor histological type       nsTGCT                                   NA                            10 (76.9)    38 (57.6)
                                sTGCT                                                                  3 (23.1)     28 (42.4)

nsTGCT, Non-Seminomatous Testicular Germ Cells Tumor; sTGCT, Seminomatous Testicular Germ Cells Tumor; and NA, Not Apply.

In the group of TGCT patients, 16.5% (13/79) had CO, of them, 38.5% (5/13) underwent orchidopexy in an average of 8.8 years of age. All patients of the TGCT group (79/79) underwent orchiectomy at TGCT diagnosis. The most frequent histological type of TGCT patients was nsTGCT \[61% (48/79)\]. The subgroup of 13 patients with TGCT and CO did not report family history of CO or TGCT, while in the subgroup of TGCT without CO, only 4.5% (3/66) patients had family history of TGCT ([Table 1](#T1){ref-type="table"}).

Genotyping {#S3.SS2}
----------

In order to identify a genetic marker associated to CO condition or to genetic susceptibility to develop TGCT in patients with CO, 6 SNVs were analyzed in this study. Three SNVs in the *KIT* gene, including rs121913507 (D816V), rs121913506 (D816H), and rs121913514 (N822K) were evaluated. While the 3 SNVs analyzed in the *AR* gene were rs201934623 (P392S), rs774171864 (A299T), and rs12014709 (c.66718624 T/G). Initially the subgroups of patients with TGCT and history of CO (*n* = 13) were compared with those patients with TGCT without CO (*n* = 66). Posteriorly, we compared the subgroup of TGCT and CO patients with isolated CO patients (*n* = 91), and finally, with healthy controls (*n* = 158; [Table 2](#T2){ref-type="table"}). Results showed that the variant rs121913507 (D816V) of the *KIT* gene was found in 1/13 (7.7%) of patients with TGCT and CO in a heterozygous form, while the rest of patients \[12/13 (92.3%)\] presented a homozygote genotype (AA). The comparison among the rest of the patients and healthy controls did not show significant statistically differences \[TGCT + CO *vs* TGCT (*P* = 0.162), TGCT + CO *vs* CO (*P* = 0.125), and TGCT + CO *vs* Controls (*P* = 0.076), respectively\]. The variant rs121913506 (D816H) of the *KIT* gene was found in heterozygous form in 11/13 (84.6%) patients with TGCT and CO, while 2/13 (15.4%) patients with TGCT and CO had a homozygote genotype (CC). In contrast to the variant rs121913507 (D816V), the comparison between the variant rs121913506 (D816H) of patients with TGCT and CO with the rest of the patients and healthy controls showed statistically significant differences \[TGCT + CO *vs* TGCT (*P* = 0.025), TGCT + CO *vs* CO (*P* = 0.015), and TGCT + CO *vs* Controls (*P* = 0.005), respectively\]. The analysis of the rs121913514 (N822K) variant of the *KIT* gene between all groups did not show any differences ([Table 2](#T2){ref-type="table"}).

###### 

Genotypic frequency of the allelic variants in *KIT* and *AR* genes in Mexican population.

  SNV                                    Patients with TGCT and CO *n* (%)         Patients with TGCT *n* (%)                 *P* value TGCT + CO *vs* TGCT   Patients with CO *n* (%)                   *P* value TGCT + CO *vs* CO   Healthy Controls *n* (%)                     *P* value TGCT + CO *vs* Control
  -------------------------------------- ----------------------------------------- ------------------------------------------ ------------------------------- ------------------------------------------ ----------------------------- -------------------------------------------- ----------------------------------
  *KIT* GENE                                                                                                                                                                                                                                                                        
  D816V (A/T) rs121913507 c.54733155     AA = 12 (92.3) AT = 1 (7.7) TT = 0 (0)    AA = 66 (100) AT = 0 (0) TT = 0 (0)        0.162                           AA = 91 (100) AT = 0 (0) TT = 0 (0)        0.125                         AA = 158 (100) AT = 0 (0) TT = 0 (0)         0.076
  D816H (G/C) rs121913506 c.54733154     GG = 0 (0) GC = 11 (84.6) CC = 2 (15.4)   GG = 0 (0) GC = 66 (100) CC = 0 (0)        0.025                           GG = 0 (0) GC = 91 (100) CC = 0 (0)        0.015                         GG = 0 (0) GC = 158 (100) CC = 0 (0)         0.005
  N822K (A/T) rs121913514 c.54733174     AA = 0 (0) AT = 13 (100) TT = 0 (0)       AA = 0 (0) AT = 66 (100) TT = 0 (0)        NA                              AA = 0 (0) AT = 89 (97.8) TT = 2 (2.2)     0.765                         AA = 0 (0) AT = 154 (97.5) TT = 4 (2.5)      0.693
  *AR* GENE                                                                                                                                                                                                                                                                         
  Intronic (T/G) rs12014709 c.66718624   TT = 0 (0) TG = 13 (100) GG = 0 (0)       TT = 2 (3.0) TG = 63 (95.5) GG = 1 (1.5)   0.736                           TT = 4 (2.5) TG = 80 (87.9) GG = 7 (7.7)   0.415                         TT = 4 (2.5) TG = 143 (90.5) GG = 11 (7.0)   0.508
  P392S (C/T) rs201934623 c.67546320     CC = 13 (100) CT = 0 (0) TT = 0 (0)       CC = 66 (100) CT = 0 (0) TT = 0 (0)        NA                              CC = 91 (100) CT = 0 (0) TT = 0 (0)        NA                            CC = 158 (100) CT = 0 (0) TT = 0 (0)         NA
  A299T (C/T) rs774171864 c.67546042     CC = 0 (0) CT = 13 (100) TT = 0 (0)       CC = 0 (0) CT = 66 (100) TT = 0 (0)        NA                              CC = 0 (0) CT = 91 (100) TT = 0 (0)        NA                            CC = 0 (0) CT = 158 (100) TT = 0 (0)         NA

NA = Not Apply.

The results of the analysis of the SNVs in the *AR* gene showed that the rs12014709 (g.67718624T \> G) variant located in the intronic region of gene presented different genotypes, however, no statistically significant differences resulted between the groups ([Table 2](#T2){ref-type="table"}). The variants rs201934623 (P392S) and rs774171864 (A299T) of the *AR* gene did not show any differences.

TGCT With History of CO Patients and the *KIT* Gene {#S3.SS3}
---------------------------------------------------

Considering that the group of patients with TGCT and CO showed significant differences in the genotypes of the *KIT* gene, we analyzed their association with significant clinical features ([Table 3](#T3){ref-type="table"}). In the first analysis, the patients 2 and 3 that presented the variant rs121913506 (D816H) in homozygous form, were young and suffered unilateral CO (although in opposite side), however, both presented different tumor histological type and only one of them developed metastasis. By the other hand, the patient 13 presented the variant rs121913507 (D816V) in heterozygous form, he had history of bilateral CO and TGCT was unilateral, the tumor type was nsTGCT and he did not develop metastasis.

###### 

Clinical features of the patients with TGCT and isolated CO.

  Patient   Age at diagnosis of TGCT           CO side     Age of orchidopexy   Tumor side   Tumor histological type   Metastasis        Clinical stage at diagnosis   Genotype
  --------- ---------------------------------- ----------- -------------------- ------------ ------------------------- ----------------- ----------------------------- -----------------
  1         16 years                           Bilateral   8 years              Right        nsTGCT                    No                I                             
  2         18 years                           Right       8 years              Right        sTGCT                     No                I                             D816H/D816H
  3         19 years                           Left        12 years             Left         nsTGCT                    Retroperitoneum   II                            D816H/D816H
  4         24 years                           Right       10 years             Right        nsTGCT                    No                I                             
  5         27 years                           Bilateral   6 years              Right        sTGCT                     No                I                             
                                                                                                                                                                       
            **Patients without orchidopexy**                                                                                                                           
                                                                                                                                                                       
  6         16 years                           Bilateral   NA                   Right        nsTGCT                    Retroperitoneum   II                            
  7         17 years                           Bilateral   NA                   Left         nsTGCT                    Pelvis            II                            
  8         22 years                           Left        NA                   Left         sTGCT                     Retroperitoneum   II                            
  9         22 years                           Bilateral   NA                   Bilateral    nsTGCT                    No                II                            
  10        23 years                           Right       NA                   Right        nsTGCT                    Lung              IV                            
  11        27 years                           Left        NA                   Left         nsTGCT                    Retroperitoneum   II                            
  12        36 years                           Bilateral   NA                   Right        nsTGCT                    Lung              III                           
  13        49 years                           Bilateral   NA                   Right        nsTGCT                    No                II                            Wild type/D816V

NA = Not Apply.

Interestingly, higher frequency of metastasis was observed in patients with TGCT and previous CO (*n* = 13) compared to those who presented only TGCT without history of CO (*n* = 66) \[53.8% (7/13) *vs* 36.4% (24/66)\] and histological type of nsTGCT \[76.9% (10/13) *vs* 57.6% (38/66)\] ([Table 1](#T1){ref-type="table"}). Furthermore, only 38.5% (5/13) of patients with TGCT and previous CO underwent orchidopexy in an age average of 8.8 years, while the rest \[8/13 (61.5%)\] of these patients did not have orchidopexy. The nsTGCT histological type \[87.5% (7/8) *vs* 60% (3/5)\], metastasis \[75% (6/8) *vs* 20% (1/5)\], and more advanced tumor stage were most frequently presented in these 8 patients that did not underwent orchidopexy ([Table 3](#T3){ref-type="table"}).

Allelic Frequencies {#S3.SS4}
-------------------

The allelic frequencies for the 3 variants of the *KIT* gene and 3 variants of the *AR* gene analyzed in this study were search in the literature and in different worldwide databases for general population, to compare these information to the allelic frequencies observed in our results. Only the variants rs121913507, rs201934623, rs774171864, and rs12014709 coincided with the reported frequencies ([Table 4](#T4){ref-type="table"}).

###### 

Allelic frequencies of the variables analyzed in the population studied.

  Gene    SNV                   Allele   ALL    EUR    AFR    EAS   SAS    AMR    MXL    Mexican
  ------- --------------------- -------- ------ ------ ------ ----- ------ ------ ------ ---------
  *KIT*   rs121913507 D816V     A        1      1      1      1     1      1      1      1
                                T        0      0      0      0     0      0      0      0
          rs121913506 D816H     G        ---    ---    ---    ---   ---    ---    ---    0.50
                                C        ---    ---    ---    ---   ---    ---    ---    0.50
          rs121913514 N822K     A        ---    ---    ---    ---   ---    ---    ---    0.49
                                T        ---    ---    ---    ---   ---    ---    ---    0.51
  *AR*    rs201934623 P392S     C        0.99   1      1      1     0.96   1      0.99   1
                                T        0.01   0      0      0     0.04   0      0.01   0
          rs774171864 A299T     C        1      1      1      1     1      1      1      0.50
                                T        0      0      0      0     0      0      0      0.50
          rs12014709 Intronic   T        0.85   0.91   0.58   1     0.96   0.91   0.96   0.49
                                G        0.15   0.09   0.42   0     0.04   0.09   0.04   0.51

There are no data available on the frequencies of the variant (---), ALL, All gnomeAD, EUR, European Ancestry, AFR, African Ancestry, EAS, East Asian Ancestry, SAS, South Asian Ancestry, AMR, Latino Ancestry, and MXL, Mexican Ancestry in Los Angeles.

Haplotype blocks conformed by variants located in the same gene were not identify. In the same way, MDR analysis did not show any significant statistical gene-gene interaction. However, the analysis of the population structure of the 4 of the 6 SNVs, a value of δ = 2.27 was identified.

Discussion {#S4}
==========

Despite the high rate of spontaneous descent during the first year of life, CO is still one of the most common congenital malformations among males worldwide, with a frequency of 1--3%; and is one of the risk factors for development TGCT ([@B2]). Besides, TGCT is the most common cancer in young men between 15 to 44 years ([@B29]), with an age-adjusted rate of 11.1 per 100,000 men (world standard). Among the solid tumors with higher mortality, TGCT are found in the fifth place with a mortality rate of 1.3 per 100,000 men ([@B14]). In spite of clinical relationship between CO and TGCT the molecular mechanisms underlying both diseases are still unknown. Significantly, although the incidence of CO and TGCT has increased worldwide, in Mexico there are few epidemiological data about both diseases.

In this study, we analyzed the clinical manifestations of patients with CO, patients with TGCT and patients with TCGT and history of CO. In the group of patients with CO we found that the incidence of bilateral disease was higher than those reported for Hispanic population \[48.3% (44/91) *vs* 19.7% (25/127)\] ([@B6]). However, other findings were similar to other studies. Surgical intervention in 70% of the patients with CO done after 2 years ([@B33]) compared with 73.6% in our study, and the family history of TGCT in our patients with CO and in Italian population \[2.2% (2/91) *vs* 2.1% (15/721; [@B11])\] ([Table 1](#T1){ref-type="table"}).

In addition, in the group of TGCT patients we did not find CO history, compared to other reports who found CO history in 5--10% ([@B16]) and 14.6% (18/123) of TGCT patients ([@B13]). On the other hand, we identify 4.5% patients with TGCT without CO (3/66) with at least one family member affected by the same neoplasm, and a global frequency of 3.8% (3/79 patients with TGCT), these were according to other authors for familiar TGCT ([@B21]; [@B24]); we also observed higher frequency of nsTGCT in our patients with TGCT, similar to Hispanic population ([@B34]; [Table 1](#T1){ref-type="table"}).

CO is an important risk factor for the development of TGCT, and this relationship has been clinically established, however, the molecular mechanism between failure in testicular descent and the development of malignancy, is still unknown ([@B9]). Several genes have been associated to the development of TGCT ([@B24]; [@B17]), but only a few of them, such as *KIT* gene expression ([@B31]), or polyQ inserts in exon 1 of the *AR* gene ([@B10]; [@B7]; [@B15]; [@B12]) have been analyzed in patients with CO, without establish a relationship between CO and TGCT.

Therefore, we focused on determine the relationship between 6 SNVs in both *KIT* and *AR* genes and TGCT and CO in Mexican population. The contrast of the patients with TGCT and history of CO with TGCT without CO, or those with CO as well as control group showed statistical differences in the presence of the homozygous form (CC) of the rs121913506 (D816H) variant of the *KIT* gene in two patients with TGCT and history of CO, these results suggested that CO patients with C allele in homozygous form might have a higher risk of development TGCT. The frequency of C allele in homozygous form in our group of TGCT Mexican patients was similar to the reported in Japanese population ([@B26]) \[2.5% (2/79) *vs* 2.9% (1/34)\]. Although the other SNVs did not show statistical differences, we consider pertinent not to discard them as important SNVs in Mexican population, therefore, these results must be explored in higher number of samples. In previous reports, the rs121913506 (D816H) variant has been considered as mutation related to TGCT ([@B20]), however, we identified the same variant in heterozygous form in the majority of patients and even in the control group, therefore our population could have a different genotype.

In the group of patients with TGCT, we considered the simultaneous presence of TGCT and CO as the most important factor, so we analyzed individually this subgroup of 13 patients, and we found that the variants rs121913507 (D816V) and rs121913506 (D816H) of the *KIT* gene were identified in 3 patients (2, 3, and 13 patients; [Table 3](#T3){ref-type="table"}); however, there were not association between these genetic variants and any particular phenotype or clinical feature. However, the results obtained from the clinical characteristics indicated that the patients with TGCT with previous CO could express a more aggressive phenotype of the TGCT, which itself is already severe ([Table 3](#T3){ref-type="table"}). These results suggest that the relationship between CO and severe TGCT phenotypes could be due to the participation of the function of multiple genes and not exclusively by *KIT* and *AR*. In particular, we observed that patients who did not undergo orchidopexy at right time had a more severe TGCT phenotype ([Table 3](#T3){ref-type="table"}). We could highlight the importance of performing orchidopexy in a timely manner, minimizing the risk and complications in the pediatric patient with CO ([Table 3](#T3){ref-type="table"}), and avoiding undescended testes to be subject to different abnormal stress conditions ([@B33]).

Additionally, the comparison of the allelic frequencies for the rs121913506 (D816H) and rs121913514 (N822K) variants in other populations was not possible due to lack of available information in the HapMap and in the project of the 1000 genomes. However, the frequencies for the allele A of the variant rs121913507 (D816V) in the *KIT* gene, and for the allele C of the variant rs201934623 (P392S) in the *AR* gene, were similar to that found in all populations. In the case of the both alleles of the variant rs774171864 (A299T), the frequencies were different to all databases, and the allelic frequencies of the variant rs12014709 were similar only with the AFR. Finally, we identified a mixed population in population structure analysis, according to previously reports for Mexican population with predominantly Amerindian and EUR ([@B27]).

In conclusion, the results of this study support the fact that CO is a risk factor for the development of TGCT at molecular level. *KIT* gene variants rs121913507 and rs121913506 might be common among TGCT and CO. However, more studies must perform to clarify these results and to find predictive biomarkers for TGCT and CO patients.
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